OVAYOZA ADELEYE: Open Payments
NPI 1538150263 · NATCHITOCHES, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,099 in 60 payments from 11 companies in 2025. Trend: 2023 $908 · 2024 $629 · 2025 $1,099
Food & beverage: $1,032Education: $66
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 13 | $247 |
| ABBVIE INC. | 15 | $228 |
| Teva Pharmaceuticals USA, Inc. | 8 | $208 |
| Otsuka America Pharmaceutical, Inc. | 6 | $121 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $61 |
| Vanda Pharmaceuticals Inc. | 3 | $54 |
| Collegium Pharmaceutical, Inc. | 3 | $54 |
| Alkermes, Inc. | 3 | $45 |
| Axsome Therapeutics, Inc. | 3 | $43 |
| Lundbeck LLC | 1 | $22 |
Products named: INGREZZA, VRAYLAR, AUSTEDO XR, ABILIFY ASIMTUFII, CAPLYTA, FANAPT, Jornay PM, ARISTADA.
Industry payments across LA — which companies pay providers there.
